Abstract 20670: Coronary Microembolization During Transfemoral Transcatheter Aortic Valve Implantation: An Intracoronary Doppler Study
Background: A postprocedural increase of the serum troponin I concentration (TnI) reflects myocardial injury and occurs frequently during transcatheter aortic valve implantation (TAVI). Periprocedural coronary microembolization is a potential cause of such injury. We therefore evaluated each step of the transfemoral TAVI procedure for coronary embolization using intracoronary Doppler (ICD) in the left anterior descending (LAD) artery.
Methods: 15 high-risk patients with severe, symptomatic aortic valve stenosis (age 79 ± 45 yrs; EuroScore 17 ± 4%) who underwent transfemoral TAVI using the balloon-expandable Edwards bioprosthesis were included. ICD examinations were recorded and evaluated off-line for high-intensity transient signals (HITS). Perioperative concentrations of TnI were serially measured within the first 72 h after TAVI, and a cardiac MRI with late gadolinium-enhancement (LGE) was performed within 7 days.
Results: HITS were detected in all patients (figure 1), mostly during the initial crossing of the native valve and positioning of the prosthesis with subsequent implantation. TnI peaked at 24 h after TAVI (3.17 ng/ml), and LGE was observed in only one single case. There was no correlation between amount of HITS and TnI area under the curve in the first 72 h after TAVI.
Conclusions: Procedural HITS were detected by ICD in all patients undergoing transfemoral TAVI. The highest amount of HITS was observed during initial valve passage and positioning of the prosthesis with subsequent implantation. However, no association was found between the number of HITS and myocardial injury, as reflected by increased serum TnI concentrations or LGE on cardiac MRI.
Author Disclosures: F. Al-Rashid: None. H. Hildebrandt: None. T. Baars: None. T. Neumann: None. F. Nensa: None. K. Nassenstein: None. D. Wendt: Other; Modest; Edwards Lifesciences. M. Thielmann: Other; Modest; Edwards Lifesciences. H. Jakob: None. E. Kottenberg: None. J. Perters: None. R. Erbel: None. G. Heusch: None. P. Kahlert: Other; Modest; Edwards Lifesciences.
- © 2014 by American Heart Association, Inc.